Global Cancer Experts Convene in Kolkata to Advance Personalized Treatment
Kolkata recently hosted a major gathering of the world's leading cancer specialists. The city welcomed scientists, clinicians, industry innovators, and policymakers from across the globe for the Conference of the Global Cancer Consortium 2026 and the 15th East Zonal Oncology Symposium. This combined event, known as GCC-EZOS 2026, created a premier international forum dedicated to advancing personalized cancer care.
Focus on Precision Oncology and Future Directions
The conference specifically centered on personalized therapy in the era of precision oncology. Experts emphasized how this approach is fundamentally transforming cancer care. Precision oncology tailors treatments to individual patients based on their unique genetic makeup, molecular profiles, and clinical characteristics. This represents a significant shift from traditional one-size-fits-all approaches to cancer treatment.
During the two-day program, specialists from India and abroad shared their extensive knowledge and experience. They discussed how personalized medicine offers new hope for more effective and targeted cancer interventions.
Showcasing Cutting-Edge Research and Technology
GCC-EZOS 2026 highlighted numerous groundbreaking developments in cancer research and treatment. The conference featured the latest breakthroughs across multiple critical areas:
- Genomics and biomarker discovery
- Artificial intelligence applications in oncology
- Immunotherapy advancements
- Targeted therapeutic approaches
- Surgical oncology innovations
- Translational research bridging laboratory findings with clinical practice
These presentations and discussions aimed to close the gap between scientific discovery and practical patient care. The event successfully connected laboratory research with real-world clinical applications.
Comprehensive Conference Program and Workshops
The conference offered a rich program of scientific sessions and symposia. Participants engaged with topics including genomics-driven therapies, targeted treatment approaches, and AI applications in oncology. Discussions also covered resistance mechanisms that can develop during cancer treatment.
Clinical and translational research presentations formed a core component of the event. These included late-breaking studies, emerging technologies, and new therapeutic developments. The conference also addressed important ethical considerations and access challenges in precision medicine.
Pre-conference workshops provided additional learning opportunities. These focused on Cardio-Oncology and Cancer Genomics, helping participants stay current with the latest developments in these specialized areas.
Host Institution and Leadership Perspectives
The Saroj Gupta Cancer Centre and Research Institute in Kolkata hosted the 6th GCC-EZOS conference. This event was organized in association with the Indian Association of Surgical Oncology. The cancer center has a remarkable history, beginning as a modest 25-bed facility in 1973. It was founded by the young radiotherapist Dr. Saroj Gupta. Today, the institute has grown into a comprehensive 311-bed cancer hospital with full modern equipment.
Dr. Amab Gupta, Director of the Saroj Gupta Cancer Centre and Research Institute, served as Chairperson of the Organizing Committee. He explained the conference's mission clearly. "By bringing together global leaders in precision oncology, we aim to translate innovation into real-world impact for patients worldwide," Dr. Gupta stated.
Dr. Vivek Rangnekar, Founding Chair of the Global Cancer Consortium, emphasized the collaborative nature of the event. He noted that the conference was specifically designed to accelerate cooperation across different scientific disciplines and international borders. This cross-pollination of ideas and expertise represents a crucial step forward in the global fight against cancer.
The gathering in Kolkata demonstrated how international collaboration can drive progress in cancer care. By sharing knowledge and resources, the global medical community moves closer to more effective, personalized treatments for cancer patients everywhere.
